Alvotech (ALVO)
ALVO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1898416/000189841626000004/0001898416-26-000004-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ALVO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Luxembourg |
| IPO year | Not reported by the screener |
| SEC CIK | 0001898416 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Luxembourg |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $586.3M |
| Net income | $27.9M |
| Operating income | $78.2M |
| Net margin | 4.8% |
| Operating margin | 13.3% |
| Revenue growth | +19.7% |
| Cash | $172.4M |
| Total assets | $1.5B |
| P/E (computed) | 61.6× |
| P/S (computed) | 2.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-31 |
| Cash and burn | $172.4M cash; operating cash flow -$12.5M a quarter. | Report 2025-12-31 |
| Shares outstanding | 312,021,375 (2025-12-31); 301,805,677 a year earlier; 248,649,506 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-06-16 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte ehf., Kopavogur, Iceland | PCAOB Form AP 2026-04-28 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $586.3M | $27.9M | -$50.2M | $172.4M | $1.3B | $586.3M | 20-F 2026-03-31 |
| FY 2024 2024-12-31 | $489.7M | -$231.9M | -$236.8M | $51.4M | $1.1B | $489.7M | 20-F 2026-03-31 |
| FY 2023 2023-12-31 | $91.4M | -$551.7M | -$312.2M | $11.2M | $960.2M | $91.4M | 20-F 2026-03-31 |
| FY 2022 2022-12-31 | $83.0M | -$513.6M | -$312.4M | $66.4M | $764.6M | $83.0M | 20-F 2025-03-27 |
| FY 2021 2021-12-31 | $36.8M | -$101.5M | -$228.2M | $17.6M | $400.9M | $36.8M | 20-F 2024-03-20 |
| FY 2020 2020-12-31 | $66.6M | -$170.0M | -$74.3M | $31.7M | $567.9M | $66.6M | 20-F 2023-03-01 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-16 |
| Latest annual report | 20-F | 2026-03-31 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 304 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.8% |
| 1 month | -22.1% |
| 3 months | +2.4% |
| Year to date | -18.3% |
| 1 year | -24.1% |
| From 52-week high | -31.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| ALVOW | Alvotech Warrant | $0.2753 |
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| WWB | Windward Bio Group AG Common Shares | $30.04 | +5.40% | $1.7B |
| VIR | Vir Biotechnology Inc. | $9.58 | -3.82% | $1.6B |
| RXRX | Recursion Pharmaceuticals Inc. | $2.90 | -8.79% | $1.8B |
| COAG | Hemab Therapeutics Holdings Inc. | $39.05 | -4.42% | $1.8B |
| MESO | Mesoblast Limited | $12.45 | -6.18% | $1.6B |
| MAZE | Maze Therapeutics Inc. | $33.90 | -1.25% | $1.9B |
| BCRX | BioCryst Pharmaceuticals Inc. | $7.45 | -2.10% | $1.9B |
| IMCR | Immunocore Holdings plc | $28.88 | -3.54% | $1.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier